logo-loader
Lexagene Holdings Inc

Full interview: LexaGene teams up with Assurance Scientific to beta test its diagnostic in humans

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) CEO Dr Jack Reegan notes that the firm is teaming up with Assurance Scientific Laboratories (ASL) to test its rapid pathogen detection technology on human urine samples. Dr Reegan says ASL has the ability to bring LexaGene's diagnostic in-house, validate it, and begin using it for clinical diagnostic.

Quick facts: Lexagene Holdings Inc

Price: $0.60

Market: TSX-V
Market Cap: $42.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc named herein, including the promotion by the Company of Lexagene Holdings Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Lexagene takes big step forward by now being recognized by FDA and CDC

Lexagene Holdings (CVE: LXG-OTCQB-LXXGF) CEO and Co-Founder Dr Jack Regan joined Steve Darling from Proactive Investors Vancouver to talk about the company now being recognized by the Food and Drug Administration and the US Centre for Disease control. Regan discussed what this means for...

3 weeks, 5 days ago

2 min read